Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 6:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 99 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: mouth spray Clear all
Withdrawn Phase 4 Interventional

VA Aripiprazole vs Esketamine for Treatment Resistant Depression

NCT05554627
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Esketamine, Aripiprazole
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 74 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
26
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 4, 2026, 6:09 AM EDT
Completed Phase 3 Interventional Results available

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

NCT02497287
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
New Haven, Connecticut • Miami, Florida • Marietta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 4, 2026, 6:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women

NCT00620854
View directory record Official record
Conditions
Osteoporosis
Interventions
Recombinant Salmon Calcitonin (rsCT), Oral Tablet, Nasal Spray
Drug
Lead sponsor
Tarsa Therapeutics, Inc.
Industry
Eligibility
45 Years to 70 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Oct 4, 2026, 6:09 AM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 4, 2026, 6:09 AM EDT
Completed Phase 4 Interventional Results available

Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine

NCT00502775
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
fluticasone furoate, fexofenadine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
42
States / cities
Little Rock, Arkansas • Albany, Georgia • Columbus, Georgia + 37 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2016 · Synced Oct 4, 2026, 6:09 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cranberry Polyphenols and Stress Resilience During Multitasking in Healthy Adults

NCT07453537
View directory record Official record
Conditions
Stress Response, Mental Stress, Multitasking Behavior and Multitasking Ability, Physiological Stress, Cognitive Symptoms, Motor Activity
Interventions
Cranberry juice, Placebo juice
Other
Lead sponsor
University of Florida
Other
Eligibility
30 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 4, 2026, 6:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Use of Jet Injection Lidocaine for Blood Draws in Young Children

NCT01890642
View directory record Official record
Conditions
Pain
Interventions
J tip, Pain Ease Spray, 1% buffered lidocaine, placebo cooling spray (normal saline spray), Sucrose
Device · Other · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
6 Months to 6 Years
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Oct 4, 2026, 6:09 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women

NCT00959764
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Oral Calcitonin Tablets, Intranasal Calcitonin, Placebo tablets and placebo intranasal spray
Drug
Lead sponsor
Tarsa Therapeutics, Inc.
Industry
Eligibility
45 Years and older · Female only
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
9
States / cities
Huntsville, Alabama • Oakland, California • Palm Desert, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 4, 2026, 6:09 AM EDT
Terminated Phase 3 Interventional Results available

An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Participants With Euvolemic or Hypervolemic Hyponatremia

NCT02020278
View directory record Official record
Conditions
Hyponatremia
Interventions
Tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
4 Years to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 4, 2026, 6:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Biological Basis of Individual Variation in Social Cooperation

NCT01566539
View directory record Official record
Conditions
Healthy
Interventions
Intranasal Oxytocin (OT) 24 IU, Intranasal Vasopressin (AVP), Intranasal Placebo, Intranasal Vasopressin (AVP) 40 IU, Lorazepam
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 30 Years
Enrollment
707 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 4, 2026, 6:09 AM EDT
Completed Phase 2 Interventional Results available

Effects of Nasulin Versus Placebo on Blood Glucose Control in Patient Volunteers With Type 2 Diabetes Mellitus

NCT00850096
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Placebo for Nasulin, Nasulin
Other · Drug
Lead sponsor
CPEX Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Chandler, Arizona • Escondido, California • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2013 · Synced Oct 4, 2026, 6:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vitamin D Absorbance Study - Clinical Trial of the Absorbance of Nano Liquid D3

NCT04885803
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
Softgel Vitamin D3, Nano Liquid Vitamin D3, 25(OH)D Blood Serum Test, Placebo Control
Dietary Supplement · Diagnostic Test · Other
Lead sponsor
Inspired Life Medical, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Le Sueur, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 4, 2026, 6:09 AM EDT
Completed Phase 4 Interventional Results available

The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease

NCT02845752
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Stiolto Respimat, Placebo Respimat
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
45 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 4, 2026, 6:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects

NCT07240116
View directory record Official record
Conditions
Healthy
Interventions
Miricorilant Treatment A, Miricorilant Treatment B, Miricorilant Treatment C, Miricorilant Treatment D
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 4, 2026, 6:09 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Topical Phenylephrine Solution in Preventing Oral Mucosa in Bone Marrow Transplant Patients Receiving Cyclophosphamide and Total Body Radiation Therapy

NCT02434146
View directory record Official record
Conditions
Neoplasm, Oral Mucosa, Transplant-Related Disorder
Interventions
Topical Phenylephrine Solution
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 4, 2026, 6:09 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Intranasal Ketorolac Trial

NCT06083571
View directory record Official record
Conditions
Headache, Migraine
Interventions
Ketorolac, Prochlorperazine, Diphenhydramine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Years to 17 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 4, 2026, 6:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Fentanyl 400 µg Sublingual Spray, Actiq® 400 µg Transmucosally, and Fentanyl Citrate Injection 100 µg Intravenously (iv)

NCT01780233
View directory record Official record
Conditions
Pain
Interventions
Fentanyl 400 µg sublingual spray, Actiq® 400 µg transmucosally, Fentanyl citrate injection 100 µg intravenously, Naltrexone 50 mg
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 4, 2026, 6:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TransMEM Gas Exchange -- Project 1, Aim 2

NCT01925729
View directory record Official record
Conditions
Middle Ear Disease, Nasal Allergy
Interventions
ragweed, histamine, pseudoephedrine, Oxymetazoline
Biological · Drug
Lead sponsor
Cuneyt M. Alper
Other
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 4, 2026, 6:09 AM EDT
Completed Phase 1 Interventional

A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia

NCT01773408
View directory record Official record
Conditions
Myelogenous Leukemia, Acute
Interventions
RO5503781 MBP, RO5503781 SDP, Idarubicin, Daunorubicin, Cytarabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Los Angeles, California • Valhalla, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 4, 2026, 6:09 AM EDT
Recruiting Phase 4 Interventional

Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy

NCT06834165
View directory record Official record
Conditions
Allergic Reactions
Interventions
Neffy, Adrenaline
Drug
Lead sponsor
ARS Pharmaceuticals, Inc.
Industry
Eligibility
4 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
La Jolla, California • Washington D.C., District of Columbia • Glenview, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 4, 2026, 6:09 AM EDT
Completed Not applicable Interventional Results available

Evaluation of the Efficacy of 3M Dry Mouth Moisturizing Spray

NCT04186806
View directory record Official record
Conditions
Xerostomia
Interventions
3M Dry Mouth Moisturizing Spray to Biotene Moisturizing Mouth Spray, Biotene Moisturizing Mouth Spray to 3M Dry Mouth Moisturizing Spray
Device
Lead sponsor
Solventum US LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 4, 2026, 6:09 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

NCT02289482
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2838232 PIB (SDD), GSK2838232 PIB (API), Placebo, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 4, 2026, 6:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX® in Healthy Subjects

NCT01507610
View directory record Official record
Conditions
Migraine
Interventions
Sumatriptan
Drug
Lead sponsor
Optinose US Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 29, 2012 · Synced Oct 4, 2026, 6:09 AM EDT
Withdrawn Phase 1 Interventional

A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression

NCT05268497
View directory record Official record
Conditions
Depression
Interventions
Esketamine, Cognitive Behavioral Therapy (CBT), Antidepressant
Drug · Behavioral
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
New Haven, Connecticut • Chicago, Illinois • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 4, 2026, 6:09 AM EDT